Article Text

PDF
Thoracic spinal cord stimulation improves functional status and relieves symptoms in patients with refractory angina pectoris: the first placebo-controlled randomised study
  1. Stephan Eddicks1,
  2. Klaus Maier-Hauff2,
  3. Michael Schenk3,
  4. Andreas Müller1,
  5. Gert Baumann1,
  6. Heinz Theres1
  1. 1Charité–Universitätsmedizin Berlin, Campus Charité Mitte, Medizinische Klinik mit Schwerpunkt Kardiologie, Angiologie und Pulmologie, Berlin, Germany
  2. 2Bundeswehrkrankenhaus Berlin, Klinik für Neurochirurgie, Zentrum für Neuromodulation, Berlin, Germany
  3. 3Charité–Universitätsmedizin Berlin, Campus Charité Mitte, Klinik für Anästhesiologie und Operative Intensivmedizin, Berlin, Germany
  1. Correspondence to:
    Dr H Theres
    Charité Hospital, Medizinische Klinik mit Schwerpunkt Kardiologie, Angiologie und Pneumologie, Schumannstr 20/21, 10117 Berlin, Germany; heinz.theres{at}charite.de

Abstract

Background: Spinal cord stimulation (SCS) is an alternative treatment option for refractory angina. Controlled trials demonstrate symptom relief and improvement in functional status. Since patients experience retrosternal prickling during active SCS, there is no option for blinding patients to active treatment or for placebo control.

Objective: To examine the therapeutic effects of subthreshold SCS in patients with refractory angina in a placebo-controlled study.

Methods: 12 responders to treatment who had already been treated with SCS for refractory angina were enrolled. Patients were randomised into four consecutive treatment arms, each for 4 weeks, with various stimulation timing and output parameters: 3×2 h/day (phase A) and 24 h/day with conventional output (phase B); 3×2 h/day with a subthreshold output (phase C); and 24 h/day with 0.1 V output, which served as control (phase D). Functional status, quality of life, Canadian Cardiovascular Society classification and nitrate usage were assessed at the end of each 4-week period.

Results: In phase D, patients showed a significant reduction in walking distance compared with phases A and C. Canadian Cardiovascular Society classification worsened in phase D compared with phases A–C. Frequency of angina attacks and the visual analogue scale were significantly worse in phase D than in phases A–C. In three patients, it was necessary to prematurely terminate phase D owing to intolerable angina attacks.

Conclusions: In this first placebo-controlled trial to apply SCS in patients with refractory angina, improvement in functional status and symptoms was revealed in phases with conventional or subthreshold stimulation, in comparison to a low-output (placebo) phase.

  • 6-MWT, 6-min walk test
  • QoL, quality of life
  • SAQ, Seattle Angina Questionnaire
  • SCS, spinal cord stimulation
  • VAS, visual analogue scale

Statistics from Altmetric.com

Footnotes

  • Published Online First 18 January 2007

  • Funding: This study was funded by Medtronic, Düsseldorf, Germany.

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles